Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
- PMID: 31749862
- PMCID: PMC6855173
- DOI: 10.5114/aoms.2019.89449
Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
Abstract
In the last several years there has been a large debate whether patients with type 2 diabetes (T2DM) should be treated as those with high or very high cardiovascular risk, and whether T2DM should be considered as equivalent to coronary heart disease (CHD). It all started in the 2001 in National Cholesterol Education Program - Adult Treatment Panel III recommendations, and the knowledge has changed on this issue at least several times. But the main problem is that due to these inconsistencies and different approaches to the cardiovascular risk of T2DM patients, we have more and more patients with T2DM not effectively treated, and diabetologists mostly focus on glucose (glucocentric approach), often forgetting about the overall cardiovascular risk of those patients. In this review we discuss the above-mentioned topic, try to give some practical suggestions, and raise the issue of whether we should start a discussion on treating all patients with T2DM as those at very high cardiovascular risk, or to at least to try to unify the definition and find such variables/risk factors which are easy to measure to help physicians to treat those patients optimally. We have obviously discussed these issues in the context of new European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) Guidelines 2019.
Keywords: CHD equivalent; diabetes; guidelines; prevention; risk stratification.
Copyright: © 2019 Termedia & Banach.
Conflict of interest statement
NK has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, Boehringer Ingelheim, Elpen, Mylan, NovoNordisk, PharmaSwiss, Sanofi, Servier and WinMedica. DPM has given talks and attended conferences sponsored by Amgen, AstraZeneca and Libytec. MB has received research grants/support from Sanofi and Valeant, and has served as a consultant for Abbott/Mylan, Akcea, Amgen, KRKA, NovoNordisk, MSD, Polfarmex, Polpharma, Sanofi-Aventis, Servier, Esperion, and Resverlogix.
Figures
References
-
- Katsiki N, Purrello F, Tsioufis C, Mikhailidis DP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18:1243–60. - PubMed
-
- Norhammar A, Bodegård J, Nyström T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692–701. - PubMed
-
- Katsiki N, Mikhailidis DP. Management of patients with type 2 diabetes mellitus and acute coronary syndrome: better be safe than sorry! J Diabetes Complications. 2019;33:465–7. - PubMed
LinkOut - more resources
Full Text Sources